{"title":"Revisiting experimental models of erectile dysfunction and their value in drug discovery and development.","authors":"Hao Wang, Eric Chung","doi":"10.1080/17460441.2025.2482065","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Erectile dysfunction (ED) is a common condition that often signals underlying endothelial dysfunction, although the underlying causative factor(s) are likely complex and multifactorial. Various animal models have been developed to provide a research platform to study ED and served as an important basis for the discovery and subsequent development of novel therapeutic drugs for ED.</p><p><strong>Areas covered: </strong>The review article provides an overview of various animal models in ED research with an emphasis on important drug target discovery relating to each specific experimental model. The authors highlight translation from basic science research to major preclinical and clinical studies in this evolving field of ED research.</p><p><strong>Expert opinion: </strong>Animal models simulate the pathological features of various types of ED and clarify their molecular mechanisms. These mechanisms aid in discovering drug targets, while established ED models also provide a basis for validating drug efficacy, safety, and specific action mechanisms. The development of techniques in detection methods, cellular experimental, and omics has a profound impact on disease prediction, model evaluation, and optimization of therapeutic modalities. On this basis, many drug therapies targeting these ED-related mechanisms, especially in the nitric oxide/cyclic guanosine monophosphate pathways have been applied in preclinical studies. However, focusing on drug development for those types of ED where phosphodiesterase 5 inhibitor therapy is limited may be more valuable.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"499-516"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2025.2482065","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Erectile dysfunction (ED) is a common condition that often signals underlying endothelial dysfunction, although the underlying causative factor(s) are likely complex and multifactorial. Various animal models have been developed to provide a research platform to study ED and served as an important basis for the discovery and subsequent development of novel therapeutic drugs for ED.
Areas covered: The review article provides an overview of various animal models in ED research with an emphasis on important drug target discovery relating to each specific experimental model. The authors highlight translation from basic science research to major preclinical and clinical studies in this evolving field of ED research.
Expert opinion: Animal models simulate the pathological features of various types of ED and clarify their molecular mechanisms. These mechanisms aid in discovering drug targets, while established ED models also provide a basis for validating drug efficacy, safety, and specific action mechanisms. The development of techniques in detection methods, cellular experimental, and omics has a profound impact on disease prediction, model evaluation, and optimization of therapeutic modalities. On this basis, many drug therapies targeting these ED-related mechanisms, especially in the nitric oxide/cyclic guanosine monophosphate pathways have been applied in preclinical studies. However, focusing on drug development for those types of ED where phosphodiesterase 5 inhibitor therapy is limited may be more valuable.
期刊介绍:
Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.